Inspired by the success of HCV-TARGET, a case study of the TARGET model in hepatitis C, TARGET PharmaSolutions was formed in February 2015. Target PharmaSolutions is a clinical data company that provides pharmaceutical partners a more efficient way to generate data that can be used to better understand the natural history of diseases, including treatment outcomes in the real world setting.
“Working with Rex Health Ventures has been a tremendous asset to TARGET PharmaSolutions. As our lead investor, they have provided critical strategic guidance and financial support that has enabled us to quickly scale.” – TARGET PharmaSolutions CEO Meg Powell
Acquired by Norwest Venture Partners.